These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 27145399)

  • 1. Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype.
    Molden E; Waade RB; Hoff M; Haslemo T
    Basic Clin Pharmacol Toxicol; 2016 Nov; 119(5):470-475. PubMed ID: 27145399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
    Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
    Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.
    Vandenberghe F; Guidi M; Choong E; von Gunten A; Conus P; Csajka C; Eap CB
    Clin Pharmacokinet; 2015 Dec; 54(12):1259-72. PubMed ID: 26129906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
    Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
    Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risperidone plasma levels, clinical response and side-effects.
    Riedel M; Schwarz MJ; Strassnig M; Spellmann I; Müller-Arends A; Weber K; Zach J; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):261-8. PubMed ID: 15565299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.
    Gunes A; Spina E; Dahl ML; Scordo MG
    Ther Drug Monit; 2008 Oct; 30(5):628-33. PubMed ID: 18708991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy.
    Paulzen M; Haen E; Hiemke C; Stegmann B; Lammertz SE; Gründer G; Schoretsanitis G
    Br J Clin Pharmacol; 2017 Aug; 83(8):1668-1675. PubMed ID: 28160505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents.
    Sherwin CM; Saldaña SN; Bies RR; Aman MG; Vinks AA
    Ther Drug Monit; 2012 Oct; 34(5):535-44. PubMed ID: 22929407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone.
    Hendset M; Molden E; Refsum H; Hermann M
    J Clin Psychopharmacol; 2009 Dec; 29(6):537-41. PubMed ID: 19910717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions.
    Paulzen M; Haen E; Gründer G; Lammertz SE; Stegmann B; Schruers KR; Walther S; Schoretsanitis G
    J Psychopharmacol; 2016 Aug; 30(8):803-9. PubMed ID: 27251417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum concentrations and side effects in psychiatric patients during risperidone therapy.
    Olesen OV; Licht RW; Thomsen E; Bruun T; Viftrup JE; Linnet K
    Ther Drug Monit; 1998 Aug; 20(4):380-4. PubMed ID: 9712460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype.
    Hendset M; Molden E; Knape M; Hermann M
    Ther Drug Monit; 2014 Feb; 36(1):80-5. PubMed ID: 24232129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder.
    Vermeulen A; Piotrovsky V; Ludwig EA
    J Pharmacokinet Pharmacodyn; 2007 Apr; 34(2):183-206. PubMed ID: 17136449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.
    Kneller LA; Abad-Santos F; Hempel G
    Clin Pharmacokinet; 2020 Jan; 59(1):51-65. PubMed ID: 31359271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.
    Mihara K; Kondo T; Yasui-Furukori N; Suzuki A; Ishida M; Ono S; Kubota T; Iga T; Takarada Y; de Vries R; Kaneko S
    Ther Drug Monit; 2003 Jun; 25(3):287-93. PubMed ID: 12766554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
    Yasui-Furukori N; Mihara K; Kondo T; Kubota T; Iga T; Takarada Y; De Vries R; Kaneko S; Tateishi T
    J Clin Pharmacol; 2003 Feb; 43(2):122-7. PubMed ID: 12616663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.
    Lisbeth P; Vincent H; Kristof M; Bernard S; Manuel M; Hugo N
    Eur J Clin Pharmacol; 2016 Feb; 72(2):175-84. PubMed ID: 26514968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.
    Zhang L; Brown SJ; Shan Y; Lee AM; Allen JD; Eum S; de Leon J; Bishop JR
    Pharmacotherapy; 2020 Jul; 40(7):632-647. PubMed ID: 32519344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.
    Calarge CA; Miller del D
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):163-9. PubMed ID: 21486167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
    Leon Jd; Susce MT; Pan RM; Wedlund PJ; Orrego ML; Diaz FJ
    Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.